



RESPONSE UNDER 37 C.F.R. § 1.116
BOX AF
EXAMINING ART UNIT GROUP 1803

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Christine L. Brakel et al.
Serial No.: 07/446,235 Group Art Unit: 1803
Filed: December 4, 1989 Examiner: Gary L. Kunz, Ph.D
For: **MODIFIED NUCLEOTIDE COMPOUNDS**

Honorable Commissioner of
Patents and Trademark
Washington, D.C. 20231

ATTENTION: BOX AF

SEP 14 1993

Sir:

Transmitted herewith is a response (Response Under 37 C.F.R. § 1.116) in the above-identified patent application.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	51	Minus	51	= 0	x 11	\$ 0
Indep	7	Minus	7	= 0	x 37	\$ 0
() First Presentation of Multiple Dependent Claims					+ 115	\$ 0
TOTAL ADDITIONAL FEE -----						\$ 0

() Charge Deposit Account No. 05-1135 in the amount of \$ ____.

() A check in the amount of \$ _____ is attached.

(X) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 05-1135: any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims and any patent application processing fees under 37 C.F.R. § 1.17.

Copies are being provided in triplicate.

Respectfully submitted,

Ronald C. Fedus
Registration No. 32,567
Attorney for Applicant(s)

SEPTEMBER 3, 1993
Date

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
575 Fifth Avenue (18th Floor)
New York, New York 10017
Tel. (212) 856-0876

Attorney's Docket No.: **Enz-47**

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks Washington, D.C. 20231

Ronald C. Fedus
Reg. No. 32,567

SEPTEMBER 3, 1993
Date